Vitamin B12 Inhibits Tau Fibrillization via Binding ... - ACS Publications

Research Article pubs.acs.org/chemneuro

Vitamin B12 Inhibits Tau Fibrillization via Binding to Cysteine Residues of Tau Saharnaz Rafiee, Kazem Asadollahi, Gholamhossein Riazi,* Shahin Ahmadian, and Ali Akbar Saboury Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran ABSTRACT: Two mechanisms underlie the inhibitory/ acceleratory action of chemical compounds on tau aggregation including the regulation of cellular kinases and phosphatases activity and direct binding to tau protein. Vitamin B12 is one of the tau polymerization inhibitors, and its deficiency is linked to inactivation of protein phosphatase 2A and subsequently hyperphosphorylation and aggregation of tau protein. Regarding the structure and function of vitamin B12 and tau protein, we assumed that vitamin B12 is also able to directly bind to tau protein. Hence, we investigated the interaction of vitamin B12 with tau protein in vitro using fluorometry and circular dichrosim. Interaction studies was followed by investigation into the effect of vitamin B12 on tau aggregation using ThT fluorescence, circular dichroism, transmission electron microscopy, and SDS-PAGE. The results indicated that vitamin B12 interacts with tau protein and prevents fibrillization of tau protein. Blocking the cysteine residues of tau confirmed the cysteine-mediated binding of vitamin B12 to tau and showed that binding to cysteine is essential for inhibitory effect of vitamin B12 on tau aggregation. SDS-PAGE analysis indicated that vitamin B12 inhibits tau aggregation and that tau oligomers formed in the presence of vitamin B12 are mostly SDS-soluble. We propose that direct binding of vitamin B12 is another mechanism underlying the inhibitory role of vitamin B12 on tau aggregation and neurodegeneration. KEYWORDS: Vitamin B12, tau protein, methylcobalamin, tau aggregation, Alzheimer’s disease

1. INTRODUCTION

GSK3β and PP2A are two critical enzymes in regulating the phosphorylation state of tau protein.3 Activation of both enzymes is a post-translational modification-dependent process. Several studies have reported the phosphorylation dependency of GSK3β and PP2A activation, while methylation is a more critical process in activation of PP2A.12 PP2A is a multimeric protein complex and the major brain serine/threonine phosphatase that dephosphorylates tau at different sites and prevents tau hyperphosphorylation.13 Decreased methylation at C-terminal leucine residue of C-subunit of PP2A indirectly affects activity and assembly of PP2A holoenzyme which finally regulates tau phosphorylation state.14 Participation of mentioned enzymes in several signaling pathways explains the mechanism of action of various kinds of active compounds on tau phosphorylation−dephosphorylation such as vitamin B12.15 Evidence suggests that enzymatic methylation of PP2A is performed by several enzymes including methionine synthase which converts homocysteine to methionine. Vitamin B12 is converted to methylcobalamin by taking a methyl group from tetrahydrofolate. The resulted methylcobalamin donates its methyl group to homocysteine, which finally is converted to methionine by methionine synthase. Therefore, vitamin B12

The presence of protein aggregates is the hallmark of several neurodegenerative diseases including Alzheimer’s and Parkinson’s disease.1 Intrinsically disordered proteins which are prone to aggregation such as tau protein and A-beta form a great portion of these aggregates.2 However, A-beta aggregates primarily accumulate in extracellular environment and tau aggregates are present in cytosol.2 Tau protein as the most important axonal microtubuleassociated protein is well-known for its role in microtubule assembly and stabilization.3 Tau also plays a critical role in various cell signaling pathways including MAPK signaling and is responsible for protection of DNA from damage upon environmental stresses.4,5 Interaction of tau with other cell components such as endoplasmic reticulum and cell membrane presents another aspect of tau functions.6,7 The broad range of tau functions is regulated by various kinds of post translational modifications including phosphorylation, glycosylation, ubiquitinylation, and truncation.8 Phosphorylation is the most important post-translational modification of tau that regulates binding of tau to microtubules.9 However, hyperphosphorylation mediates detachment of tau from microtubule polymers and subsequent accumulation of tau as neurofibrillary tangles.10 Phosphorylation of tau is under intense control via a wide range of protein kinases and phosphatases.11 © 2017 American Chemical Society

Received: June 22, 2017 Accepted: August 25, 2017 Published: August 25, 2017 2676

DOI: 10.1021/acschemneuro.7b00230 ACS Chem. Neurosci. 2017, 8, 2676−2682

Research Article

ACS Chemical Neuroscience

Figure 1. Fluorescence quenching of tau and CB-tau protein by B12 at various temperatures. (a) Emission spectra of tau protein in the presence of various concentrations of B12 at 25 °C. Tau fluorescence at 304 nm was quenched. Emission spectra at 360 and 405 nm was also changed due to conversion of methylcobalamin to thiolatocobalamin. (b) Fluorescence emission spectra of tau protein at 37 °C which shows quenching at 304 nm. Spectra has changed at 360 and 405 nm as well. However, the change at these regions is less intense in comparison to 25 °C. (c) Stern−Volmer plot for interaction of B12 with tau at 25 and 37 °C. The upward curvature of the Stern−Volmer plot has decreased with temperature increase. Solid and open circles represent plots at 25 and 37 °C, respectively. (d,e) Titration of B12 into CB-tau solution at 25 and 37 °C, respectively. Blockade of cysteine residues resulted in omission of spectral change at 360 and 405 nm that shows participation of cysteines in interaction. (f) Stern−Volmer plot for titration of B12 into CB-tau solution at 25 and 37 °C, solid and opened circles, respectively. The upward curvature has been removed after blocking of cysteines and both plots are similar in shape. (g) Titration of B12 into tau solution at 50 °C. Spectral change at 360 and 405 nm has omitted, like CB-tau quenching experiments, due to partial folding of tau at high temperatures that results in inaccessibility of cysteine residues. (h) Stern−Volmer plot for quenching of tau fluorescence at 50 °C. The upward curvature has been omitted that indicates absence of thiolatocobalamin formation. In all experiments, 1 μM of tau protein has been quenched with various concentrations of B12 up to 20 μM. The arrows indicate the regions of spectra affected by formation of thiolatocobalamin from methylcobalamin.

we investigated binding of vitamin B12 to tau protein and assessed the effect of vitamin B12 on tau aggregation in vitro.

deficiency results in PP2A inactivation, tau hyperphosphorylation, subsequent tau aggregation, and finally neural degeneration.15−17 Structural changes of tau upon direct binding to different ligands are responsible for the effect of other groups of biologically active molecules on tau aggregation.18 One of the most important structural changes, which affect tau aggregation, is the formation of disulfide bonds.19 It has been reported that formation of intermolecular disulfide bonds accelerates tau aggregation, while intramolecular disulfide bonds could prevent aggregation.20 Hence, it is anticipated that native and cysteine mutated tau isoforms containing only one cysteine residue accumulate faster than tau isoforms containing two cysteine residues.21 In this context, investigation of the effect of cysteine blockers, disulfide bond reducers, and oxidants on tau aggregation have illustrated the key role of tau cysteine residues in tau aggregation.18−20 Structure and function of vitamin B12 inside the cells suggest the ability of vitamin B12 to directly bind to tau protein and affect its polymerization. In addition, vitamin B12 is able to interact with thiol groups which encourages this assumption since tau protein has two exposed cysteine residues.22 Hence,

2. RESULTS AND DISCUSSION We hypothesized that the role of vitamin B12 in neurodegeneration is not only exerted via activation of PP2A but also through direct binding of vitamin B12 to tau protein. Hence, at first step vitamin B12 binding to tau was characterized using fluorescence spectroscopy. Intrinsic fluorescence of tau in the presence of vitamin B12 was recorded in two different temperatures, 25 and 37 °C (Figure 1a and b). Addition of methylcobalamin, the active form of vitamin B12, into the protein solution resulted in quenching of tyrosine fluorescence, the only fluorophore of tau protein, at 304 nm. In addition to the obvious decrease of intensity at 304 nm, two other regions of spectra at 360 and 405 nm were affected as well. Previous investigations on spectroscopic profile of methylcobalamin and thiolatocobalamin have indicated that spectral changes in these regions are due to interaction of methylcobalamin with thiol groups and formation of thiolatocobalamin from methylcobalamin which suggests participation of cysteine residues of tau in interaction.23 Higher quantum yield of methylcobalamin in 2677


Research Article

ACS Chemical Neuroscience both of these regions and lower and higher extinction coefficient of methylcobalamin than thiolatocobalamin at 360 and 405 nm, respectively, are responsible for the observed changes.23 In order to confirm participation of thiols in interaction cysteine residues of tau were blocked by acrylamide and titration experiments were performed using cysteine-blocked tau (CB-tau) at the same conditions. If formation of thiolatocobalamin be responsible for fluorescence spectral changes, blockade of cysteine residues of tau would prevent it. Emission spectra of CB-tau protein showed a normal quenching of tau fluorescence at 304 nm with no spectral changes at 360 and 405 nm (Figure 1d and e). These data reinforce this suggestion that methylcobalamin binds to tau protein via cysteine residues. To get a better insight into vitamin B12/tau protein interaction, the Stern−Volmer plot24 was drawn by using the eq 1: F0 = 1 + KSV[B12] F

Figure 2. Vitamin B12 prevents thermal collapse of tau protein. Continuous thermal collapse of tau protein has been prevented in the presence of vitamin B12. Here, 10 μM tau protein, solid line, was incubated with 10 and 20 μM vitamin B12, dashed and long dashed line, respectively. Fluorescence intensities have been normalized against the fluorescence intensity of the control sample to compensate the effect of vitamin B12 on fluorescence quenching of tau.

(1)

where F0 and F are the fluorescence intensity in the absence and presence of various concentrations of vitamin B12 ([B12]) at 304 nm, respectively (Figure 1c). As Figure 1c shows the Stern−Volmer plot has an upward curvature which reduces by temperature increase. The upward curvature of Stern−Volmer plot is due to a combined static and dynamic quenching.24 Thus, it could be concluded that at higher temperatures only one kind of quenching is dominant. If the formation of thiolatocobalamin be responsible for the static quenching, hence blocking of cysteine residues would eliminate the upward curvature of Stern−Volmer plot. Stern−Volmer plot for fluorescence quenching of CB-tau confirmed that the formation of thiolatocobalamin accounts for static mechanism of quenching (Figure 1f). Omission of upward curvature of Stern−Volmer plot at high temperatures suggested that cysteine residues of tau are inaccessible at higher temperatures which could be due to partial collapse of tau protein at these temperatures.25 In order to examine this, quenching of tau by vitamin B12 was performed at 50 °C. The emission spectra of tau protein at 50 °C upon addition of vitamin B12 was very similar to CB-tau emission spectra without spectral change at 360 and 405 nm (Figure 1g). Moreover, the upward curvature of Stern−Volmer plot was omitted which indicated inaccessibility of cysteine residues at higher temperatures (Figure 1h). It should be noted that incomplete elimination of upward curvature of Stern−Volmer plot even after blocking of cysteine residues could be due to incomplete blocking of cysteine residues, the Ellman’s essay showed that only 85% of the cysteine residues are blocked. During our experiments we also found that thermal collapse of tau protein is concomitant with decrease in fluorescence intensity of tau protein. Since cysteine residues are placed at the vicinity of the collapsed regions of tau, binding of vitamin B12 to cysteine residues of tau must prevent partial folding of this region and decrease in fluorescence intensity. Tau protein was incubated with various concentrations of vitamin B12 and the fluorescence intensity of tau at 304 nm was recorded by excitation at 275 nm. The slope of graphs in Figure 2 measures the rate of decrease in fluorescence intensity as a result of thermal collapse of tau. The lower rate of fluorescence intensity decrease in the presence of vitamin B12 indicated the inhibitory role of vitamin B12 in thermal collapse of tau. However,

vitamin B12 could not prevent complete thermal collapse of tau which is due the small overlap between vitamin B12 binding region and tau regions involved in thermal collapse.25 Fluorescence studies on tau and CB-tau emission spectra proposed that vitamin B12 binds to cysteine residues of tau. To confirm fluorescence data, CD experiments were performed using both tau and CB-tau species. CD spectra of tau protein is determined by a single negative peak around 200 nm due to unfolded nature of tau. Titration of vitamin B12 into tau solution resulted in intense decrease in ellipticity at 200 nm and appearance of a shoulder around 220 nm, which indicated secondary structural changes of tau protein upon vitamin B12 binding (Figure 3a). However, injection of vitamin B12 into CB-tau solution illustrated small changes in ellipticity at 200 nm and around 220 nm which means there is a negligible effect of vitamin B12 on CB-tau secondary structure (Figure 3b). In order to quantitate the effect of vitamin B12 on the secondary structure content of tau and CB-tau, the CD spectra were deconvoluted using CDNN 2.1 software. The percentage of different secondary structures are presented in Table 1. As the values indicate the content of helix, random coil and betaturns of tau have been increased, while the beta-structures have decreased in the presence of vitamin B12. Although the secondary structure content of tau protein has been affected by vitamin B12, CB-tau structure remained uninfluenced which illustrates the key role of free thiols in interaction. The importance of cysteine residues in tau aggregation process as well as increase in helix and random coil content of tau protein upon binding to vitamin B12 suggest that vitamin B12 is a potential modulator of tau aggregation. To illustrate this, tau was assembled in the presence of various concentrations of vitamin B12 and the aggregation process was followed by recording ThT fluorescence at various time periods. ThT fluorescence was increased rapidly in control samples, while the presence of vitamin B12 effectively inhibited tau fibrillization (Figure 4a). It can be concluded from ThT results that fibrillization is inhibited intensely in vitamin B12/ tau ratio of 1:1 and higher concentrations of vitamin has a small effect on the extent of aggregation which could be due to presence of only one specific binding site for vitamin B12 on tau protein. Carrying out aggregation experiments using CB-tau showed that binding of B12 to tau protein via cysteine residues 2678


Research Article


vitamin B12 prevents tau protein fibrillization, the reduced peak intensity of tau CD spectra in the presence of B12 emphasizes on formation of small oligomers. Although ThT results indicated complete fibrillization of CBtau, CD spectra of aggregated CB-tau showed only a small decrease in ellipticity at 200 nm and no fibrillization (Figure 4d). The disagreement in CD spectra and ThT fluorescence in the case of CB-tau could be due to the effect of alkylation of cysteine residues, a hydrophobic moiety, on ThT fluorescence properties. It has been shown previously that introduction of hydrophobic residues into protein sequence affects ThT fluorescence.27,28 It also has been reported that mutation of cysteine to alanine prevents aggregation of tau protein that explains our CD results.21 Since both ThT fluorescence and CD spectroscopy are error prone methods for following aggregation progress, electron microscopy was used for observation of fibrils. TEM micrographs show that the presence of vitamin B12 effectively inhibits tau fibrillization, while vitamin B12 has no effect on aggregation extent of CB-tau (Figure 5). The electron micrographs of aggregated CB-tau illustrate that blocking of cysteine residues of tau prevent formation of tau fibrils and only small oligomers are formed that was confirmed by CD spectra. However, vitamin B12 cannot prevent formation of these small oligomers. In order to examine inhibitory effect of vitamin B12 on tau aggregation, aggregated proteins were loaded on a continuous SDS-polyacrylamide gel. SDS-PAGE analysis illustrated that vitamin B12 could efficiently prevent formation of tau aggregation (Figure 6). The relatively equal intensity of monomeric tau bands on SDS-PAGE in various concentrations of vitamin B12 on one hand and the presence and absence of tau oligomers in TEM micrographs of aggregated tau in the presence of 10 and 80 μM vitamin B12, respectively, on the other hand proposes that tau oligomers are SDS-soluble. Contrary to the effect of vitamin B12 on tau aggregation, vitamin B12 has no significant inhibitory effect on CB-tau aggregation and formed oligomers, observed by TEM, are SDSinsoluble (Figure 6). It is worth mentioning that the presence of monomeric CB-tau in the presence of 80 μM vitamin B12 could be due to prevention of aggregation at high concentrations of vitamin B12 or SDS-solubility of aggregated CB-tau. SDS-PAGE results indicated that binding of tau protein to vitamin B12 causes formation of less condensed aggregates into which SDS could penetrate efficiently and solubilize the aggregates. However, the absence of vitamin B12 in the CB-tau aggregates results in highly condensed SDS-insoluble aggregates.

Figure 3. Effect of vitamin B12 on secondary structure of tau. (a) Secondary structural change of tau protein in the presence of various concentrations of B12 shows intense decrease in negative ellipticity at 200 nm. (b) CD spectra of CB-tau in the presence of B12. The small effects of B12 on the structure of CB-tau show that blocking of cysteine residues prevents interaction of vitamin B12 with tau protein. Here 10 μM tau and CB-tau, solid line, have been titrated with 10, 30, and 50 μM B12, dotted, dashed, and long dashed lines, respectively.

is necessary for inhibitory action of vitamin B12 on tau aggregation (Figure 4b). Although vitamin B12 does not prevent CB-tau aggregation, it affects the nucleation process of tau at high concentrations that could be explained by nonspecific interaction of B12 with tau protein at high concentrations of vitamin. Aggregation of tau protein gives rise to higher content of beta-sheet secondary structures which is easily detectable from the red-shifted CD spectra of tau fibrils.26 CD spectra of aggregated tau protein in the presence and absence of vitamin B12 confirmed ThT results indicating the inhibitory effect of B12 in tau fibrillization (Figure 4c). The red-shift of aggregated tau CD spectrum concomitant with decreased peak intensity indicated the formation of tau protein fibrils, while the absence of red-shift in the presence of vitamin B12 demonstrated the inhibitory effect of vitamin B12 on tau fibrillization. Although

3. CONCLUSION Several studies have reported the deficiency of vitamin B12 in neurodegenerative diseases.15,16 It has been illustrated that

Table 1. Secondary Structure Content of Tau and CB-Tau in the Presence of Vitamin B12 α-helixa b

a

β-antiparallel

β-parallel

β-turn

random coil

B12 concn (μM)

tau

CB-tau

tau

CB-tau

tau

CB-tau

tau

CB-tau

tau

CB-tau

0 10 30 50

5.2 7 7.7 8.2

6.3 6.7 6.4 6.6

32.4 23.3 21.6 22.4

32 32 31.5 32

3.5 3.2 3.2 3.5

3.9 4 4 4

24.4 30.5 30.9 29.9

22.8 22.6 22.5 22

34.5 37 36.6 36

35 34.7 35.6 35.4

The values represent the percentage of secondary structures. b10 μM of protein has been titrated with various concentrations of vitamin B12. 2679


Research Article


Figure 4. Effect of B12 on tau and CB-tau aggregation. (a) B12 effectively inhibits formation of tau fibrils. (b) Aggregation of CB-tau was not affected by vitamin B12. Circles (black), squares (red), triangles (green), crosses (purple), and plus marks (yellow) represent ThT fluorescence of aggregated proteins in the presence of 0, 10, 30, 50, and 80 μM vitamin B12 at various time periods. (C) CD spectra of aggregated tau in the absence and presence of various concentrations of vitamin B12. CD spectra of aggregated tau protein shows decrease in ellipticity and red-shift toward higher wavelengths that indicates tau protein fibrils have been formed. However, the absence of redshift in the presence of B12 indicates the inhibition of fibril formation. (d) CD spectra of aggregated CB-tau in the presence of various concentrations of vitamin B12 shows that blocking of cysteine residues inhibits protein aggregation. However, decrease in ellipticity at 200 nm could be due to formation of tau oligomers. CD spectra of monomeric protein, solid black line, and aggregated protein in the presence of 0, 10, 30, 50, and 80 μM of vitamin B12 is presented by circles (black), squares (red), triangles (green), crosses (purple), and plus marks (yellow), respectively.

vitamin B12 deficiency causes deactivation of phosphatase enzymes, especially PP2A, which are responsible for preventing tau protein hyperphosphorylation.12 However, there is no report on the direct binding of vitamin B12 on tau protein. Tau protein has an extended structure with two accessible cysteine residues that provides tau with this ability to coordinate metal ions.10 Moreover, vitamin B12 is also able to interact with thiol groups.23 We hypothesized that vitamin B12 interacts with tau protein via cysteine residues and influences tau structure and function. To examine our hypothesis, interaction of vitamin B12 with tau and CB-tau and its effect on aggregation of two protein species was investigated. It can be concluded from our results that vitamin B12 could directly bind to tau protein via cysteine residues of tau. Inhibition of continuous thermal collapse of tau by vitamin B12 also proposes that conformation of tau/vitamin B12 complex is different from the conformation of temperature-dependent folded tau protein. The conformation of vitamin B12/tau protein complex hinders stacking of tau monomers and fibrillation of tau protein. Moreover, capping of cysteine residues of tau by vitamin B12 also enhances the inhibitory effect of vitamin B12 on tau aggregation. It is also noteworthy that although the effect of vitamin B12 deficiency in the Alzheimer’s brains mostly exerted via

inactivation of PP2A and hyperphosphorylation of tau protein, direct binding of vitamin B12 to tau protein and tau aggregation inhibition as a result can be an alternative mechanism.

4. METHODS Methylcobalamin, dithiothreitol (DTT), ammonium sulfate and thioflavin T (ThT) were purchased from Sigma Company. Vitamin B12, B12, and methylcobalamin have been used interchangeably throughout the text. 4.1. Tau Purification. Tau protein was purified by our previously published method.29 Briefly, 1N/4R tau protein was expressed in E. coli BL21 (DE3). The bacterial pellet was recovered and heated for 30 min in boiling water. The cooled bacterial suspension reached 2.5% PCA, and after 15 min at room temperature it was centrifuged at 20 000g for 20 min. The supernatant was treated with ammonium sulfate (45% saturated) and was centrifuged as above. The pellet was resuspended and treated with 2% trichloroacetic acid. After centrifugation, the pellet was treated with 2% TCA and centrifuged. The supernatant was removed as tau protein and buffer exchanged using a Sephadex G-25 desalting column. 4.2. Fluorescence Spectroscopy. Structural changes of tau protein upon binding of vitamin B12 were assessed by recording emission spectra of tau in the presence of various concentrations of vitamin at 25 and 37 °C. Here, 1 mL of 1 μM tau protein solution in 20 mM Tris buffer containing 20 mM sodium sulfate was poured into 2680


Research Article


vitamin B12 (10 and 20 μM). Protein solution was excited at 275 nm and emission was recorded in a gradual temperature increase from 30 to 80 °C. 4.3. Cysteine Blocking. Tau cysteine residues were alkylated using acrylamide.30 Briefly, tau protein in 100 mM Tris buffer at pH 8.8 was reduced using 10 mM DTT for 2 h at 37 °C. Then, 2 M acrylamide was added to the protein solution and incubation was continued for an additional 2 h. The buffer of cysteine-blocked tau (CB-tau) solution was exchanged using a Sephadex G-25 desalting column. The yield of blocking reaction was assessed using Ellman’s assay according to the standard protocol,31 which showed higher than 85% blockade of cysteine residues. 4.4. Tau Protein Assembly. Tau protein solution (10 μM) in the presence of various concentrations (0−80 μM) of vitamin B12 and 1 mM DTT was incubated at 37 °C and reaction was initiated by addition of 0.1 mg/mL heparin. (1 mM DTT was added daily to samples containing DTT until the end of the aggregation process.) The assembly process was followed by removing the desired volume of the reaction mixture and incubating with ThT (20 μM) for 15 min. Increase in ThT fluorescence upon binding to aggregated proteins was recorded using the Cary Eclipse fluorimeter by excitation and emission at 344 and 370−600 nm, respectively. 4.5. Circular Dichroism (CD) Spectroscopy. CD spectroscopy was used for measurement of conformational changes of tau protein in the presence of vitamin B12 and following the protein assembly process in the presence and absence of DTT and B12. To assess the conformational changes of tau protein in the presence of B12, a solution of tau protein containing 10 μM protein was titrated with vitamin B12 and CD spectra were recorded using an AVIV CD spectrophotometer. In order to record CD spectra of aggregated protein, the aggregation reaction mixture was removed at the end of the aggregation period and CD spectra were recorded. 4.6. Transmission Electron Microscopy (TEM). Aggregated tau protein was mounted on a carbon-coated mesh grid and incubated at ambient temperature for 2 min. The protein filaments were negatively stained using 2% uranyl acetate and were viewed by using a Hitachi HU12A transmission electron microscope. 4.7. SDS-PAGE Analysis of Aggregated Proteins. Aggregated proteins were loaded and separated on a 6% continuous SDS-PAGE gel using a phosphate buffer system under reducing conditions.32 In each well, 5 μM of aggregated protein was loaded. After the electrophoresis run was finished, the gel was stained with Coomassie brilliant blue G250.

Figure 5. TEM micrographs of tau filaments in the absence (left panel) and presence (right panel) of vitamin B12. The presence of B12 effectively inhibits tau filament formation while it has no effect on CBtau aggregation.

■

AUTHOR INFORMATION

Corresponding Author

*Mailing address: P.O. Box: 13145-1384, Tehran, Iran. Telephone: +98 9121255924. E-mail: [email protected]. ORCID

Gholamhossein Riazi: 0000-0001-5434-4042 Author Contributions

G.H.R. and K.A. conceived and managed the project; S.R. performed most of the experiments. K.A. and S.R. designed experiments, analyzed data, and wrote the manuscript. S.A. contributed to TEM experiments, A.A.S. contributed to the fluorescence data analysis and manuscript reviewing. G.H.R. contributed to data analysis and reviewed the manuscript.

Figure 6. SDS-PAGE of aggregated proteins in the presence of various concentrations of vitamin B12. In each well, 5 μg of aggregated protein was loaded. The numbers indicate the concentration of vitamin B12. The arrowhead indicates monomeric tau protein.

Notes

The authors declare no competing financial interest.

a fluorescence cuvette. Protein solution was excited at 275 nm (slit 5 nm), and emission spectra were recorded from 285 to 380 (slit 10 nm) using a Cary Eclipse fluorescence spectrophotometer equipped with a Varian thermal controller. For measurement of melting point of tau protein, tau protein solution (10 μM) was incubated with various concentrations of

■

ACKNOWLEDGMENTS We kindly appreciate Ms. Ghasemi and Ms. Shafieezadeh for their help in performing fluorescence and TEM experiments. 2681


Research Article


■

(20) Furukawa, Y., Kaneko, K., and Nukina, N. (2011) Tau protein assembles into isoform- and disulfide-dependent polymorphic fibrils with distinct structural properties. J. Biol. Chem. 286, 27236−46. (21) Bhattacharya, K., Rank, K. B., Evans, D. B., and Sharma, S. K. (2001) Role of Cysteine-291 and Cysteine-322 in the Polymerization of Human Tau into Alzheimer-like Filaments. Biochem. Biophys. Res. Commun. 285, 20−26. (22) Hogenkamp, H. P. C., Bratt, G. T., and Kotchevar, A. T. (1987) Reaction of alkylcobalamins with thiols. Biochemistry 26, 4723−4727. (23) Rodgers, Z. L., Shell, T. A., Brugh, A. M., Nowotarski, H. L., Forbes, M. D. E., and Lawrence, D. S. (2016) Fluorophore Assisted Photolysis of Thiolato-Cob(III)alamins. Inorg. Chem. 55, 1962−9. (24) Lakowicz, J. R. (2006) Quenching of Fluorescence. In Principles of Fluorescence Spectroscopy, pp 277−330, Springer US, Boston, MA. (25) Ciasca, G., Campi, G., Battisti, A., Rea, G., Rodio, M., Papi, M., Pernot, P., Tenenbaum, A., and Bianconi, A. (2012) Continuous Thermal Collapse of the Intrinsically Disordered Protein Tau Is Driven by Its Entropic Flexible Domain. Langmuir 28, 13405−13410. (26) Jeganathan, S., Von Bergen, M., Mandelkow, E. M., and Mandelkow, E. (2008) The natively unfolded character of Tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry 47, 10526−10539. (27) Iyer, A., Roeters, S. J., Schilderink, N., Hommersom, B., Heeren, R. M. A., Woutersen, S., Claessens, M. M. A. E., and Subramaniam, V. (2016) The Impact of N-terminal Acetylation of alpha-Synuclein on Phospholipid Membrane Binding and Fibril Structure. J. Biol. Chem. 291, 21110. (28) Hawe, A., Sutter, M., and Jiskoot, W. (2008) Extrinsic fluorescent dyes as tools for protein characterization. Pharm. Res. 25, 1487−99. (29) Asadollahi, K., Rafiee, S., Riazi, G. H., Pooyan, S., and Afrasiabi, A. (2016) Trichloroacetic acid treatment as a tricky way for rapid purification of 1N/4R tau protein. Protein Expression Purif. 118, 98− 104. (30) Brune, D. C. (1992) Alkylation of cysteine with acrylamide for protein sequence analysis. Anal. Biochem. 207, 285−90. (31) Ellman, G. L. (1959) Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82, 70−77. (32) Weber, K., Pringle, J. R., and Osborn, M. (1972) Measurement of molecular weights by electrophoresis on SDS-acrylamide gel. Methods Enzymol. 26, 3−27.

REFERENCES

(1) Ballatore, C., Lee, V. M.-Y., and Trojanowski, J. Q. (2007) Taumediated neurodegeneration in Alzheimer’s disease and related disorders. Nat. Rev. Neurosci. 8, 663−72. (2) LaFerla, F. M., and Oddo, S. (2005) Alzheimer’s disease: Aβ, tau and synaptic dysfunction. Trends Mol. Med. 11, 170−176. (3) Mandelkow, E. M., and Mandelkow, E. (2011) Biochemistry and cell biology of Tau protein in neurofibrillary degeneration. Cold Spring Harbor Perspect. Biol., a006247. (4) Leugers, C. J., Koh, J. Y., Hong, W., and Lee, G. (2013) Tau in MAPK activation. Front. Neurol. 4, 161. (5) Sultan, A., Nesslany, F., Violet, M., Bégard, S., Loyens, A., Talahari, S., Mansuroglu, Z., Marzin, D., Sergeant, N., Humez, S., Colin, M., Bonnefoy, E., Buée, L., and Galas, M. C. (2011) Nuclear Tau, a key player in neuronal DNA protection. J. Biol. Chem. 286, 4566−4575. (6) Meier, S., Bell, M., Lyons, D. N., Ingram, A., Chen, J., Gensel, J. C., Zhu, H., Nelson, P. T., and Abisambra, J. F. (2015) Identification of Novel Tau Interactions with Endoplasmic Reticulum Proteins in Alzheimer’s Disease Brain. J. Alzheimer’s Dis. 48, 687. (7) Pooler, A. M., Usardi, A., Evans, C. J., Philpott, K. L., Noble, W., and Hanger, D. P. (2012) Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol. Aging 33, 431.e27. (8) Mietelska-Porowska, A., Wasik, U., Goras, M., Filipek, A., and Niewiadomska, G. (2014) Tau protein modifications and interactions: Their role in function and dysfunction. Int. J. Mol. Sci. 15, 4671−4713. (9) Shahpasand, K., Uemura, I., Saito, T., Asano, T., Hata, K., Shibata, K., Toyoshima, Y., Hasegawa, M., and Hisanaga, S. -i. (2012) Regulation of Mitochondrial Transport and Inter-Microtubule Spacing by Tau Phosphorylation at the Sites Hyperphosphorylated in Alzheimer’s Disease. J. Neurosci. 32, 2430−2441. (10) Buée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A., and Hof, P. R. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work. Brain Res. Rev. 33, 95−130. (11) Cuchillo-Ibanez, I., Seereeram, A., Byers, H. L., Leung, K.-Y., Ward, M. a, Anderton, B. H., and Hanger, D. P. (2008) Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J. 22, 3186−3195. (12) Zhou, X.-W., Gustafsson, J.-Å., Tanila, H., Bjorkdahl, C., Liu, R., Winblad, B., and Pei, J.-J. (2008) Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol. Dis. 31, 386−394. (13) Bottiglieri, T., Arning, E., Wasek, B., Nunbhakdi-Craig, V., Sontag, J.-M., and Sontag, E. (2012) Acute Administration of L-Dopa Induces Changes in Methylation Metabolites, Reduced Protein Phosphatase 2A Methylation, and Hyperphosphorylation of Tau Protein in Mouse Brain. J. Neurosci. 32, 9173−9181. (14) Sontag, J.-M., and Sontag, E. (2014) Protein phosphatase 2A dysfunction in Alzheimer’s disease. Front. Mol. Neurosci. 7, 16. (15) Moore, E., Mander, A., Ames, D., Carne, R., Sanders, K., and Watters, D. (2012) Cognitive impairment and vitamin B12: a review. Int. Psychogeriatrics 24, 541−556. (16) Kifle, L., Ortiz, D., and Shea, T. B. (2009) Deprivation of folate and B12 increases neurodegeneration beyond that accompanying deprivation of either vitamin alone. J. Alzheimer's Dis. 16, 533−40. (17) Wei, W., Liu, Y.-H., Zhang, C.-E., Wang, Q., Wei, Z., Mousseau, D. D., Wang, J.-Z., Tian, Q., and Liu, G.-P. (2011) Folate/vitamin-B12 prevents chronic hyperhomocysteinemia-induced tau hyperphosphorylation and memory deficits in aged rats. J. Alzheimer's Dis. 27, 639−50. (18) Crowe, A., James, M. J., Lee, V. M. Y., Smith, A. B., Trojanowski, J. Q., Ballatore, C., and Brunden, K. R. (2013) Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation. J. Biol. Chem. 288, 11024−11037. (19) Schweers, O., Mandelkow, E. M., Biernat, J., and Mandelkow, E. (1995) Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments. Proc. Natl. Acad. Sci. U. S. A. 92, 8463−8467. 2682


Vitamin B12 Inhibits Tau Fibrillization via Binding ... - ACS Publications

Recommend Documents